Long–term Neurodevelopment outcomes to Prenatal Antipsychotic Medication Exposure: Systemic Review

INTRODUCTION: Peak incidence for many psychiatric disorders occurs in reproductive years. We don’t have FDA-approved drugs or clinical guidelines. The main cause of pharmacological suspension in pregnancy is the lack of knowledge of their effects on the product. Gathering information on this regard becomes crucial so we can avoid relapses or exacerbation OBJECTIVES: Describe neurodevelopmental effects in children ≥ 6 months exposed to antipsychotics prenatally. METHODS: PROSPERO-CRD42020170314. Using MeSH terms in 5 databases, without language and time restriction, obtaining n=3932. After review and exclusion n=24 were obtained for qualitative review. (Figure 1). RESULTS: Of 20 case reports 4 had more ambivalence results (Table 1). In the cohort studies, exposure may cause short-term delay at 6 months but no significant difference at 12 months (Table 2). [Table: see text] [Table: see text] Image: CONCLUSIONS: Most are case reports, hence the importance of collecting this information, not ignoring it due to lack of methodological rigor. The intent is not to conclude that prenatal exposure to antipsychotics doesn’t have long-term neurodevelopmental effects, rather documenting the available evidence contributing to an informed clinical decision. DISCLOSURE OF INTEREST: None Declared